Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TaxErb Protocol: Docetaxel + Carboplatin Chemotherapy in Combination with Cetuximab in Advanced or Metastatic NSCLC
2006-004526-90Phase 2Completed
- Sponsor
- Klinik Löwenstein
- Start
- Jan 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, docetaxel and carboplatin in non-small cell lung cancer (NSCLC), sponsored by Klinik Löwenstein. Primary endpoint: Objective tumor response. Started Jan 2007; status: completed.
02
Drugs
cetuximabdocetaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-004526-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004526-90.